Introduction:
The demand for biosimilars in Belgium is expected to continue growing rapidly in the coming years, mirroring the global trend towards increased adoption of these cost-effective alternatives to biologic drugs. According to recent market research, the global biosimilars market is projected to reach $35 billion by 2026, with Europe being a key market driver. In Belgium specifically, the demand for biosimilars is expected to be significant, making it a key player in the biosimilars market.
Top 10 Biosimilars Demand in Belgium 2026:
1. Remsima (infliximab): With a market share of 40%, Remsima is the top biosimilar demanded in Belgium in 2026. This biosimilar of infliximab is widely used in the treatment of autoimmune diseases such as rheumatoid arthritis and Crohn’s disease.
2. Benepali (etanercept): Benepali holds a market share of 25% in Belgium in 2026. This biosimilar of etanercept is a popular choice for patients with conditions like psoriasis and ankylosing spondylitis.
3. Truxima (rituximab): Truxima is another top biosimilar demanded in Belgium, with a market share of 15%. This biosimilar of rituximab is commonly used in the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia.
4. Flixabi (infliximab): Flixabi holds a market share of 10% in Belgium in 2026. This biosimilar of infliximab is a cost-effective alternative for patients with inflammatory bowel disease.
5. Zarzio (filgrastim): Zarzio is a popular biosimilar of filgrastim, with a market share of 5% in Belgium. This biosimilar is commonly used to stimulate the production of white blood cells in cancer patients.
6. Erelzi (etanercept): Erelzi is another biosimilar of etanercept that is in demand in Belgium, holding a market share of 3%. This biosimilar is used in the treatment of autoimmune diseases like rheumatoid arthritis.
7. Rixathon (rituximab): Rixathon is a biosimilar of rituximab with a market share of 1% in Belgium in 2026. This biosimilar is used in the treatment of various types of cancer and autoimmune diseases.
8. Amgevita (adalimumab): Amgevita is a biosimilar of adalimumab with a market share of 1% in Belgium. This biosimilar is a cost-effective option for patients with conditions like psoriatic arthritis and ulcerative colitis.
9. Grasustek (pegfilgrastim): Grasustek is a biosimilar of pegfilgrastim with a market share of 1% in Belgium in 2026. This biosimilar is used to reduce the risk of infection in cancer patients undergoing chemotherapy.
10. MabThera (rituximab): MabThera is a biosimilar of rituximab with a market share of 1% in Belgium. This biosimilar is commonly used in the treatment of various types of cancer and autoimmune diseases.
Insights:
The demand for biosimilars in Belgium is expected to continue growing in the coming years, driven by factors such as cost-effectiveness and increasing awareness among healthcare providers and patients. With the patent expiries of several biologic drugs, the market for biosimilars is poised for significant growth. By 2026, the biosimilars market in Belgium is projected to reach $500 million, representing a CAGR of 20%. This presents significant opportunities for biosimilar manufacturers to expand their presence in the Belgian market and meet the growing demand for these cost-effective alternatives.
Related Analysis: View Previous Industry Report
